Clinical Trial Update: Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating the combination of atezolizumab and WT1 dendritic cell vaccination with platinum/pemetrexed-based first-line therapy fo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• Atezolizumab (atezolizumab)
• WT1 dendritic cell vaccine (WT1 dendritic cell vaccine)

Snippet

Sponsor: University Hospital, Antwerp | Conditions: Malignant Pleural Mesothelioma | Phase 1, Phase 2 | Status: RECRUITING